Development of a Pre-clinical Candidate for Progressive Fibrosing Interstitial Lung Disease Targeting gp130 (an IL-6 Family Cytokine) Inhibition

Primo Thera CO., Ltd.

PRIMO THERA

RESPIRATORY | **Candidate**

Product Type	Small molecule
Indication	Auto-immune Diseases & Progressive Fibrosing Interstitial Lung Disease
Target	Glycoprotein(gp)130: an IL-6 family cytokines common receptor, essential for signal transducing
MoA(Mechanism of Action)	Our approach selectively inhibits IL-6 family cytokine signaling by disrupting the gp130 signaling complex via its extracellular domain, prevalent in inflammatory cells, epithelium, and fibroblasts.
Competitiveness	**Novel Multi-Functional Mechanism:** • **Simultaneously controls IL-6 family cytokines** (e.g., IL-6, IL-11, OSM & LIF) that drive autoimmune inflammation, fibrotic progression, **and critically, regulate the transition from chronic inflammation to fibrosis.** • Offers **superior efficacy** over single-target agents by addressing the comprehensive pathogenic cascade of these diseases. **Addressing High Unmet Medical Needs:** • Poised to deliver a **transformative solution** for complex autoimmune diseases and aggressive PF-ILDs, areas critically lacking effective treatments. **Optimal Small Molecule Profile:** • **Immunogenicity-free** with **flexible, personalized dosing** (e.g., potential for oral, once-daily administration). • Enhances **patient convenience and adherence**, while potentially reducing manufacturing costs.
Development Stage	Candidate
Route of Administration	Oral Administration, Once daily